Physician profile
Todd Bonvallet
NPI 1952376337
$26,992.07
in general payments reported to CMS, 2019-2025
33 companies · $1,397 in 2025
The $1,397 reported for 2025 was less than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,257 · 2020: $7,830 · 2021: $4,944 · 2022: $1,820 · 2023: $774 · 2024: $2,969 · 2025: $1,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,148 · Travel and Lodging: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,148.13 |
| Travel and Lodging | $992.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Precision Spine, INC. | $14,069.75 | 2019-2020 | |
| Camber Spine Technologies LLC | $2,773.11 | 2021-2022 | |
| Nanovis LLC | $1,994.73 | 2019-2024 | |
| Spineology INC. | $1,982.98 | 2020-2025 | Optimesh Expandable Interbody Fusion System |
| Implanet America, INC. | $1,902.29 | 2024 | |
| Spinal Elements, INC. | $661.63 | 2021-2022 | |
| Centinel Spine, LLC | $609.72 | 2024 | Prodisc L |
| Getset Surgical INC | $535.94 | 2023 | Goplf! Posterior Lateral Fusion System |
| Neo Spine USA, INC. | $330.26 | 2025 | Neo Pedicle Screw System |
| Nuvasive, INC. | $293.14 | 2022-2023 | Simplify Cervical Artificial Disc |
| Zavation Medical Products, LLC | $223.39 | 2020-2021 | |
| Carlsmed, INC. | $199.62 | 2025 | Aprevo |
| Alphatec Spine, INC | $164.59 | 2025 | Invictus Open, Identiti, Lif |
| Augmedics INC. | $163.13 | 2025 | Xvision |
| Cerapedics INC. | $149.58 | 2024-2025 | I-Factor Peptide Enhanced Bone Graft |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $126.50 | 2021-2024 | |
| Intrinsic Therapeutics | $126.05 | 2025 | Barricaid Acd (Annular Closure Device) |
| Seaspine Orthopedics Corporation | $114.63 | 2022 | |
| Globus Medical, INC. | $89.82 | 2022-2025 | Senza |
| Choice Spine, LLC | $86.05 | 2020 | |
| Horizon Therapeutics Plc | $84.50 | 2020-2022 | |
| Bioventus LLC | $63.69 | 2021-2025 | Bonescalpel & Sonicone (O.R.), Xcell |
| Theragen, INC. | $32.50 | 2021 | |
| Si-Bone, INC. | $29.39 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $26.74 | 2025 | |
| Avanos Medical | $25.32 | 2019 | |
| Stryker Corporation | $22.61 | 2019 | |
| Smith+Nephew, INC. | $22.13 | 2021 | |
| Abbott Laboratories | $21.27 | 2021 | |
| Orthofix Medical, INC. | $21.00 | 2022 | |
| Pacira Therapeutics, INC. | $16.60 | 2021 | |
| Arteriocyte Medical Systems, INC. | $15.20 | 2025 | Magellan |
| Ethicon US, LLC | $14.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$334,937.39 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Bonvallet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.